Camzyos Capsules 2.5 mg

USDailyMed:Mavacamten AU:D C01EB24(WHO) AU:S4(Prescription only)BR:Class C1(Other controlled substances)CA:℞-onlyUS:℞-onlyEU:Rx-only 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione 1642288-47-8 117761397 11265 DB14921 57876199 QX45B99R3J D12265 ChEMBL4297517 Interactive image CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1Key:RLCLASQCAPXVLM-NSHDSACASA-N Mavacamten, sold under the brand nameCamzyos, is amedicationused to treat obstructivehypertrophic cardiomyopathy. Mavacamten is a small-molecule allostericand cardiacmyosininhibitor.It was developed by MyoKardia, a subsidiary of Bristol Myers Squibb.In clinical studies, mavacamten has demonstrated significant efficacy in reducing cardiac muscle contractility by targeting the sarcomere hypercontractility that is one of the characteristics of hypertrophic cardiomyopathy and inhibits excessive myosin actin cross-bridge formation, shifting the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. Mavacamten was approved for medical use in the United States in April 2022.The USFood and Drug Administration(FDA) considers it to be afirst-in-class medication.